Immunity Against AAV in Crigler Najjar Patient

Genethon49 enrolled

Overview

The proposed research protocol aims at addressing these points by pre-screening CN patients for their AAV serology in link with their medical history and current medical status. A first objective is to assess the presence of neutralizing AAV antibodies in the serum of CN patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Crigler Najjar Syndrome

Interventions

Blood sample for immunologyBIOLOGICAL

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * The patient has a Crigler-Najjar syndrome * The molecular diagnosis has been confirmed by UGT1A1 gene DNA sequencing Exclusion criteria: * The patient is liver transplanted * The patient is suffering from severe associated pathologies precluding further enrolment in a future interventional clinical study

Locations (1)

Hopital Antoine Béclère

Clamart, France

Outcomes

Primary Outcomes

To assess the presence of neutralizing AAV antibodies in the serum of CN patients

Time frame: 1 day visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.